![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Clinical Trials
Oxford leads first trial investigating dosing with alternating vaccines
The University of Oxford is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery...
Clinical Trials
Ampio Announces Early Positive Data in Phase 1 Trial of Inhaled Ampion in COVID-19 Respiratory Distress
Ampio Pharmaceuticals, Inc., a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced early positive data from its ongoing...
Clinical Trials
Aizon Launches GxP AI Bioreactor Application for the Pharma Industry to Scale Manufacturing & Quality
Aizon launches its Bioreactor Application, the pharma industry’s first predictive analysis and deep knowledge management application. The Aizon Bioreactor Application adds the bioreactor process...
Clinical Trials
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
Rigel Pharmaceuticals, Inc. announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological,...
Clinical Trials
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
Novavax, Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint,...
Clinical Trials
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19
Grifols, a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...
Clinical Trials
Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio
Intravacc, a world leader in translational research and development of vaccines, announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read